NicOx is a biopharmaceutical company focused on developing and commercializing nitric oxide-donating drugs to meet unmet medical needs. NicOx applies its proprietary nitric oxide-donating technology to develop a portfolio of New Chemical Entities (NCEs) in the areas of inflammation and cardio-metabolic disease. The company’s main therapy areas include osteoarthritis, acute pain, cardiovascular diseases, neurodegenerative diseases, respiratory diseases, liver diseases and dermatology. Naproxcinod, a proprietary NCE is in phase III clinical trails for treating osteoarthritis. NicOx also possess a pipeline containing multiple nitric oxide-donating NCEs, which are in clinical trails for treating prevalent and underserved diseases such as hypertension, glaucoma and chronic obstructive pulmonary disease (COPD).